|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 55005 | A randomized phase III study comparing Gemcitabine plus Carboplatin versus Carboplatin monotherapy in patients with advanced eepithelial ovarian carcinoma who failed first-line platinum based therapy Intergroup AGO-EORTC-NCIC CTG trial (EORTC 55005) |
| 55963 | A randomized phase III study for the treatment of recurrent epithelial ovarian cancer: Chemotherapy alone versus chemotherapy followed by secondary cytoreductive surgery in patients with a treatment-free interval of more than 12 months-trial 55963 |
| 16996O | Open label phase II study on RFS 2000 (9 nitro-camptothecin,9-NC) administered as a "5 days on-2 days off" oral tratment in adavanced ovarian cancer. EORTC study 16996 O |
| 15982 | An international field study of the reliability and validity of a disease specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cance. |
| 55951 | Taxol or Oxaliplatin in platinum-pretreated advanced ovarian cancer patients |
| 22925 | Phase III study to evaluate a Cisplatin-Cyclophosphamide combination and an abdomino-pelvic irradiation followed by a pelvic boost in completely resected high risk stage Ia/Ib and Ic/IIa/IIb epithelial ovarian carcinomas |
| 55931 | EORTC-NCIC-Scottish-Scandinavian-Intergroup phase III comparison of a combination of Taxol-platinum and a combination of cyclophosphamide-platinum chemotherapy in the treatment of advanced epithelial ovarian cancer |
| 04925 | A phase II second and third line chemotherapy study with taxotere (RP56976) in patients with advanced ovarian cancer, recurrent and/or refractory to platinum therapy |
| 55904 | Phase III study to evaluate platinum based chemotherapy as an adjuvant to surgery in early ovarian cancer patients |
| 55892 | Phase II study of high dose Epirubicin in patients with advanced ovarian carcinoma |
| 16893OV | Phase II trial of GR63178A in patients with advanced ovarian carcinoma |
| 55891 | Phase II study of etoposide in patients with recurrent or advanced granulosa-theca cell tumor of the ovary |
| 55881 | Phase II trial of Fotemustine (S 100360) in patients with advanced ovarian carcinoma |
| 55882 | PHASE II TRIAL OF FLUTAMIDE IN PATIENTS WITH ADVANCED OVARIAN CARCINOMA. |
| 55875 | Intraperitoneal Cisplatin versus no further treatment: A phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based induction chemotherapy and cytoreductive surgery |
| 55876 | Phase II study of D-TRP-6-LHRH (decapeptyl) in patients with advanced ovarian carcinoma |
| 55865 | Phase III study for the treatment of ovarian cancer FIGO stages IIB and C, III and IV |
| 04861 | Etude clinique phase II 4' -0-tetrahydropyranyl adriamycine (THP-ADM-1609 RB) |
| 16851G | Phase II Study of Chemotherapy with 5-Aza-2'-Deoxycytidine in Patients with Advanced Epithelial Cancer of the Ovary |
| 55862 | Phase II study of a combination of cis-diammine-dichloro-platinum, vinblastine, and bleomycin in patients with recurrent or advanced dysgerminoma |
| 55856 | Phase II trial for intraperitoneal cisplatin in ovarian cancer FIGO III, IV minimal residual disease after chemotherapy and cytoreductive surgery |
| 55854 | Phase II Randomized Chemotherapy Trial of CHIP vs CACP in Patients with Advanced Ovarian Cancer Refractory or Recurrent After First-Line Chemotherapy with CBDCA (Summary Last Modified 05/88) |
| 16841D | Phase II Chemotherapy with Menogaril in Patients with Advanced Epithelial Cancer of the Ovary |
| 55843 | Phase II trial of a combination of cis-diammine-dichloro-platinum, vinblastine, and bleomycin in patients with recurrent or advanced granulosa-theca cell tumors of the ovary |
| 55012 | A phase III study of Cisplatin plus Topotecan followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as first line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer. |
| 55955 | A randomised trial in relapsed ovarian cancer: Early treatment based on CA 125 levels alone vs Delayed treatment based on conventional clinical indicators - MRC OV05 and EORTC/GCCG 55955 |
| 90061 | Multicenter parallel phase II trial of BI 2536 administrered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions (NOCI) |
| 55051 | A multi-national randomized Phase III GCIG Intergroup Study comparing Pegylated Liposomal Doxorubicin and Carboplatin (CaC) versus Paclitaxel and Carboplatin (TC) in patients with epithelial ovarian cancer in late relapse (>6 months). |
| 55981 | A randomized trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) versus Paclitaxel/Carboplatin (TC) in the treatment of women with Advanced Ovarian Cancer |
| 55971 | Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma. |
| 55041 | A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer |
| 16991O | Open label Phase II study on XR5000 administered as a 5 day infusion in advanced ovarian cancer:EORTC study 16991O |
| 16921O | Phase II trial with Taxotere in patients with advanced ovarian cancer |
| 16902O | Phase II trial of Elsamitrucin (BMY 28090) in patients with advanced ovarian cancer |